First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
dividend - Orion historically maintains high dividend payout ratios (60-80% of earnings) typical of mature European pharma companies…
Rising rates create modest headwinds through higher discount rates applied to long-duration pharma cash flows…
Watch on earnings: EUR/USD exchange rate and EUR/SEK cross-rate (impacts export competitiveness and API input costs), European pharmaceutical price index trends (government reimbursement rate changes), Nordic healthcare expenditure as % of GDP (budget allocation to pharmaceuticals).
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $2.2B to $2.1B as proprietary drug pipeline progress: phase iii trial results, regulatory approvals in eu markets.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.